Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma

Title: Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma

Full Record
Other Related Research

Abstract

A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.

Inventors:: Jurisson, Silvia S.; Quinn, Thomas P.; Giblin, Michael F.

Issue Date:: 2003-08-19

Research Org.:: Univ. of Missouri, Columbia, MO (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1531460

Patent Number(s):: 6607709

Application Number:: 09/686,700

Assignee:: The Curators of the University of Missouri (Columbia, MO)

Patent Classifications (CPCs):: A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K51/08 - Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
A61K51/086 - {the peptide being alphaMSH, alpha melanocyte stimulating hormone}

Show less

DOE Contract Number:: FG02-93ER61661

Resource Type:: Patent

Resource Relation:: Patent File Date: 2000-10-11

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE

Citation Formats


                    Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma.  United States: N. p., 2003. 
        Web.

Copy to clipboard


                    Jurisson, Silvia S., Quinn, Thomas P., & Giblin, Michael F. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma.  United States.

Copy to clipboard


                    Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F. Tue .  
        "Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma".  United States.  https://www.osti.gov/servlets/purl/1531460.

Copy to clipboard


                    
@article{osti_1531460,

  title        = {Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma},

  author       = {Jurisson, Silvia S. and Quinn, Thomas P. and Giblin, Michael F.},

  abstractNote = {A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {2003},

  month        = {8}

}

Copy to clipboard

Patent:

View Patent

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE Patents and OSTI.GOV collections:

Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma

Patent Jurisson, Silvia S.; Quinn, Thomas P.; Giblin, Michael F.

A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.
Full Text Available
New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents

Patent Katti, Kattesh V [Columbia, MO]; Volkert, Wynn A [Columbia, MO]; Ketring, Alan R [Columbia, MO]; ...

A class of diagnostic and therapeutic compounds derived from phosphinimines that include ligands containing either a single phosphinimine functionality or both a phosphinimine group and a phosphine or arsine group, or an aminato group, or a second phosphinimine moiety. These phosphinimine ligands are complexed to early transition metal radionuclides (e.g. .sup.99m Tc or .sup.186 Re/.sup.188 Re) or late transition metals (e.g., .sup.105 Rh or .sup.109 Pd). The complexes with these metals .sup.186 Re/.sup.188 Re, .sup.99m Tc and .sup.109 Pd exhibit a high in vitro and high in vivo stability. The complexes are formed in high yields and can be neutralmore »« less
Full Text Available
Compositions and methods involving methyladenosine phosphorylase in the diagnosis and treatment of proliferative disorders

Patent Olopade, Olufunmilayo I.

Disclosed are novel nucleic acid and peptide compositions comprising methylthioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and identification of tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.
Full Text Available
Methylthioadenosine phosphorylase compositions and methods of use in the diagnosis and treatment of proliferative disorders

Patent Olopade, Olufunmilayo I.

Disclosed are novel nucleic acid and peptide compositions comprising methythlioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and idenification tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.
Full Text Available
Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use

Patent Srivastava, Suresh C [Setauket, NY]; Meinken, George E [Middle Island, NY]

Radiopharmaceutical compositions including .sup.117m Sn labeled stannic (Sn.sup.4+) chelates are provided. The chelates are preferably polyhydroxycarboxylate, such as oxalates, tartrates, citrates, malonates, gluconates, glucoheptonates and the like. Methods of making .sup.117m Sn-labeled (Sn.sup.4+) polyhydroxycarboxylic chelates are also provided. The foregoing pharmaceutical compositions can be used in methods of preparing bone for scintigraphical analysis, for radiopharmaceutical skeletal imaging, treatment of pain resulting from metastatic bone involvement, treatment of primary bone cancer, treatment of cancer resulting from metastatic spread to bone from other primary cancers, treatment of pain resulting from rheumatoid arthritis, treatment of bone/joint disorders and to monitor radioactively the skeletalmore » system.« less
Full Text Available

Similar Records